Matches in Wikidata for { <http://www.wikidata.org/entity/Q66039413> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q66039413 description "clinical trial" @default.
- Q66039413 description "ensayu clínicu" @default.
- Q66039413 description "klinisch onderzoek" @default.
- Q66039413 description "клінічне випробування" @default.
- Q66039413 name "Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy" @default.
- Q66039413 name "Zoledronic Acid - Letrozole Adjuvant Synergy Trial" @default.
- Q66039413 type Item @default.
- Q66039413 label "Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy" @default.
- Q66039413 label "Zoledronic Acid - Letrozole Adjuvant Synergy Trial" @default.
- Q66039413 prefLabel "Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy" @default.
- Q66039413 prefLabel "Zoledronic Acid - Letrozole Adjuvant Synergy Trial" @default.
- Q66039413 P1050 Q66039413-1992E907-53A2-4B09-B234-1B6F70A634FB @default.
- Q66039413 P1132 Q66039413-8EBBA745-B629-483F-B3ED-99242B97C51C @default.
- Q66039413 P131 Q66039413-0905ABAC-7607-47F6-A282-D19996A455D3 @default.
- Q66039413 P1476 Q66039413-0726608C-F69E-4A5F-AFF8-5FFE229E616A @default.
- Q66039413 P17 Q66039413-670355EE-323C-4CD0-B85C-CA8EF79FD66E @default.
- Q66039413 P2899 Q66039413-735F9D4D-C1D0-4BDA-A042-2837BCCDF040 @default.
- Q66039413 P3098 Q66039413-A255873E-9C17-4FAF-A23E-D3011B3DAE41 @default.
- Q66039413 P31 Q66039413-51D1A686-2535-41E7-8E8A-61D9BB8EC85F @default.
- Q66039413 P4135 Q66039413-F7558D46-93C8-40DF-82BB-A45EBE996EAC @default.
- Q66039413 P4844 Q66039413-4FE5323F-27CE-4C30-98D4-79A04B1FEF95 @default.
- Q66039413 P580 Q66039413-1ACC87B8-2DE0-4E25-AB74-71B33C2B71CD @default.
- Q66039413 P582 Q66039413-BC3B1E77-B9A1-4997-AD22-7EB58A5A6A48 @default.
- Q66039413 P6099 Q66039413-DA444499-D606-42B0-BE98-669AB5C0209C @default.
- Q66039413 P6153 Q66039413-D2E90E4C-6DA0-4267-8381-75F5F67294A4 @default.
- Q66039413 P6153 Q66039413-D4F32F70-3810-4462-AD68-7CDF541DA48F @default.
- Q66039413 P8363 Q66039413-877C2EC3-2076-42CE-A3BD-FB2CFD737571 @default.
- Q66039413 P859 Q66039413-A08CF278-86C0-4478-AB81-775E252E4667 @default.
- Q66039413 P1050 Q165328 @default.
- Q66039413 P1132 "+602" @default.
- Q66039413 P131 Q1183 @default.
- Q66039413 P1476 "An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy" @default.
- Q66039413 P17 Q30 @default.
- Q66039413 P2899 "+18" @default.
- Q66039413 P3098 "NCT00050011" @default.
- Q66039413 P31 Q30612 @default.
- Q66039413 P4135 "+85" @default.
- Q66039413 P4844 Q26963 @default.
- Q66039413 P580 "2002-09-01T00:00:00Z" @default.
- Q66039413 P582 "2009-01-01T00:00:00Z" @default.
- Q66039413 P6099 Q42824827 @default.
- Q66039413 P6153 Q30270310 @default.
- Q66039413 P6153 Q30282233 @default.
- Q66039413 P8363 Q78089383 @default.
- Q66039413 P859 Q507154 @default.